BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/29/2018 4:56:27 AM | Browse: 529 | Download: 537
Publication Name World Journal of Gastroenterology
Manuscript ID 39087
Country/Territory Canada
Received
2018-03-29 04:29
Peer-Review Started
2018-03-29 09:25
To Make the First Decision
2018-04-27 02:06
Return for Revision
2018-04-27 06:04
Revised
2018-05-09 13:03
Second Decision
2018-06-25 08:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-06-25 19:19
Articles in Press
2018-06-25 19:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-08-27 01:38
Publish the Manuscript Online
2018-08-27 07:22
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
Manuscript Source Invited Manuscript
All Author List Jason Reinglas, Lorant Gonczi, Zsuzsanna Kurti, Talat Bessissow and Peter L Lakatos
Funding Agency and Grant Number
Corresponding Author Peter L Lakatos, DSc, MD, PhD, Professor, Division of Gastroenterology, Montreal General Hospital C7-200, McGill University Health Center, 1650 Cedar Avenue, Quebec H3G1A4, Canada. kislakpet99@gmail.com
Key Words Inflammatory bowel disease; Small molecule; Positioning; Biologic; Therapeutic
Core Tip Anti-tumor necrosis factor therapy should be considered as first-line therapy in patients with com­plicated Crohn’s disease and in acute-severe ulcera­tive colitis. Beyond these specific circumstances, the positioning of novel biologics and small molecules de­pends on the patient’s medical history, preference and disease phenotype. The efficacy and safety of using immunomodulatory therapy can be enhanced by ad­hering to therapeutic algorithms and using a ‘treat-to-target’ approach. The risks for adverse events due to poor disease control outweigh the risks associated with early aggressive therapy. In the setting of clinical and bio­chemical remission, following at least 6 mo of combined immunosuppressive therapy, consideration can be made to withdrawing thiopurine therapy in the correct patient with close follow-up.
Publish Date 2018-08-27 07:22
Citation Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582
URL http://www.wjgnet.com/1007-9327/full/v24/i32/3567.htm
DOI http://dx.doi.org/10.3748/wjg.v24.i32.3567
Full Article (PDF) WJG-24-3567.pdf
Manuscript File 39087-Review.docx
Answering Reviewers 39087-Answering reviewers.pdf
Audio Core Tip 39087-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 39087-Conflict-of-interest statement.pdf
Copyright License Agreement 39087-Copyright license agreement.pdf
Peer-review Report 39087-Peer-review(s).pdf
Scientific Misconduct Check 39087-Scientific misconduct check.pdf
Scientific Editor Work List 39087-Scientific editor work list.pdf